115 related articles for article (PubMed ID: 15373770)
1. Pegylated and conventional interferon-alpha induce comparable transcriptional responses and inhibition of tumor growth in a human melanoma SCID mouse xenotransplantation model.
Krepler C; Certa U; Wacheck V; Jansen B; Wolff K; Pehamberger H
J Invest Dermatol; 2004 Oct; 123(4):664-9. PubMed ID: 15373770
[TBL] [Abstract][Full Text] [Related]
2. The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma.
Suarez-Kelly LP; Kemper GM; Duggan MC; Stiff A; Noel TC; Markowitz J; Luedke EA; Yildiz VO; Yu L; Jaime-Ramirez AC; Karpa V; Zhang X; Carson WE
Oncotarget; 2016 Dec; 7(49):81172-81186. PubMed ID: 27783987
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of growth and metastasis of orthotopic human prostate cancer in athymic mice by combination therapy with pegylated interferon-alpha-2b and docetaxel.
Huang SF; Kim SJ; Lee AT; Karashima T; Bucana C; Kedar D; Sweeney P; Mian B; Fan D; Shepherd D; Fidler IJ; Dinney CP; Killion JJ
Cancer Res; 2002 Oct; 62(20):5720-6. PubMed ID: 12384530
[TBL] [Abstract][Full Text] [Related]
4. Safety of pegylated interferon-alpha-2a in adjuvant therapy of intermediate and high-risk melanomas.
Loquai C; Nashan D; Hensen P; Luger TA; Grabbe S; Sunderkötter C; Schiller M
Eur J Dermatol; 2008; 18(1):29-35. PubMed ID: 18086586
[TBL] [Abstract][Full Text] [Related]
5. Type I consensus interferon (CIFN) gene transfer into human melanoma cells up-regulates p53 and enhances cisplatin-induced apoptosis: implications for new therapeutic strategies with IFN-alpha.
Mecchia M; Matarrese P; Malorni W; D'Agostino G; Sestili P; Santini SM; Gauzzi MC; Venditti M; Mazzocchi A; Parmiani G; Belardelli F; Ferrantini M
Gene Ther; 2000 Jan; 7(2):167-79. PubMed ID: 10673721
[TBL] [Abstract][Full Text] [Related]
6. Expression modes of interferon-alpha inducible genes in sensitive and resistant human melanoma cells stimulated with regular and pegylated interferon-alpha.
Certa U; Wilhelm-Seiler M; Foser S; Broger C; Neeb M
Gene; 2003 Oct; 315():79-86. PubMed ID: 14557067
[TBL] [Abstract][Full Text] [Related]
7. Difference of interferon-α and interferon-β on melanoma growth and lymph node metastasis in mice.
Roh MR; Zheng Z; Kim HS; Jeung HC; Rha SY; Chung KY
Melanoma Res; 2013 Apr; 23(2):114-24. PubMed ID: 23358428
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma.
Hwu WJ; Panageas KS; Menell JH; Lamb LA; Aird S; Krown SE; Williams LJ; Chapman PB; Livingston PO; Wolchok JD; Houghton AN
Cancer; 2006 Jun; 106(11):2445-51. PubMed ID: 16639739
[TBL] [Abstract][Full Text] [Related]
9. Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon Alfa immunotherapy.
Lesinski GB; Kondadasula SV; Crespin T; Shen L; Kendra K; Walker M; Carson WE
J Natl Cancer Inst; 2004 Sep; 96(17):1331-42. PubMed ID: 15339971
[TBL] [Abstract][Full Text] [Related]
10. High density oligonucleotide array analysis of interferon- alpha2a sensitivity and transcriptional response in melanoma cells.
Certa U; Seiler M; Padovan E; Spagnoli GC
Br J Cancer; 2001 Jul; 85(1):107-14. PubMed ID: 11437411
[TBL] [Abstract][Full Text] [Related]
11. Comparison of a treatment strategy combining CCI-779 plus DTIC versus DTIC monotreatment in human melanoma in SCID mice.
Thallinger C; Werzowa J; Poeppl W; Kovar FM; Pratscher B; Valent P; Quehenberger P; Joukhadar C
J Invest Dermatol; 2007 Oct; 127(10):2411-7. PubMed ID: 17508024
[TBL] [Abstract][Full Text] [Related]
12. Synergistic therapy of human ovarian carcinoma implanted orthotopically in nude mice by optimal biological dose of pegylated interferon alpha combined with paclitaxel.
Tedjarati S; Baker CH; Apte S; Huang S; Wolf JK; Killion JJ; Fidler IJ
Clin Cancer Res; 2002 Jul; 8(7):2413-22. PubMed ID: 12114447
[TBL] [Abstract][Full Text] [Related]
13. Novel growth and death related interferon-stimulated genes (ISGs) in melanoma: greater potency of IFN-beta compared with IFN-alpha2.
Leaman DW; Chawla-Sarkar M; Jacobs B; Vyas K; Sun Y; Ozdemir A; Yi T; Williams BR; Borden EC
J Interferon Cytokine Res; 2003 Dec; 23(12):745-56. PubMed ID: 14769151
[TBL] [Abstract][Full Text] [Related]
14. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents.
Studeny M; Marini FC; Dembinski JL; Zompetta C; Cabreira-Hansen M; Bekele BN; Champlin RE; Andreeff M
J Natl Cancer Inst; 2004 Nov; 96(21):1593-603. PubMed ID: 15523088
[TBL] [Abstract][Full Text] [Related]
15. The antitumor effects of interferon-alpha are maintained in mice challenged with a STAT1-deficient murine melanoma cell line.
Badgwell B; Lesinski GB; Magro C; Abood G; Skaf A; Carson W
J Surg Res; 2004 Jan; 116(1):129-36. PubMed ID: 14732359
[TBL] [Abstract][Full Text] [Related]
16. Administration of pegylated interferon-alpha-2a or -2b does not induce sickness behavior in Lewis rats.
Loftis JM; Wall JM; Pagel RL; Hauser P
Psychoneuroendocrinology; 2006 Nov; 31(10):1289-94. PubMed ID: 17049181
[TBL] [Abstract][Full Text] [Related]
17. Sylatron: a pegylated interferon for use in melanoma.
Patel JN; Walko CM
Ann Pharmacother; 2012 Jun; 46(6):830-8. PubMed ID: 22619474
[TBL] [Abstract][Full Text] [Related]
18. Real-life experience with pegylated interferon and conventional interferon in adjuvant melanoma therapy.
Rozati S; Naef L; Levesque MP; French LE; Dummer R
J Immunother; 2013 Jan; 36(1):52-6. PubMed ID: 23211621
[TBL] [Abstract][Full Text] [Related]
19. The side population of ovarian cancer cells is a primary target of IFN-alpha antitumor effects.
Moserle L; Indraccolo S; Ghisi M; Frasson C; Fortunato E; Canevari S; Miotti S; Tosello V; Zamarchi R; Corradin A; Minuzzo S; Rossi E; Basso G; Amadori A
Cancer Res; 2008 Jul; 68(14):5658-68. PubMed ID: 18632618
[TBL] [Abstract][Full Text] [Related]
20. Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation.
Reu FJ; Bae SI; Cherkassky L; Leaman DW; Lindner D; Beaulieu N; MacLeod AR; Borden EC
J Clin Oncol; 2006 Aug; 24(23):3771-9. PubMed ID: 16801630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
